Circadian Rhythm Sleep Disorders Market - Global Analysis and Industry Forecast, 2013 - 2019

Submitted by: Submitted by

Views: 126

Words: 458

Pages: 2

Category: Business and Industry

Date Submitted: 06/04/2014 05:58 AM

Report This Essay

Sleep disorder is a deviation in the normal sleeping pattern. It can also be defined as difficulty related to sleeping that includes falling asleep at inappropriate time, excessive sleep and abnormal behavior associated with the sleep. Sleep disorders are classified into four categories namely, dyssomnias, parasomnias, proposed sleep disorder and medical disorder. Dyssomnia is the disturbance in quality, time and amount of sleep. It is further classified as intrinsic sleep disorder, circadian rhythm sleep disorder and extrinsic sleep disorder.

Browse Full Report with TOC: http://www.transparencymarketresearch.com/circadian-rhythm-sleep-disorders.html

The various types of CRSD are as follows:

• Delayed Sleep Phase Disorder (DSP)

• Jet Lag Disorder

• Irregular Sleep-Wake Rhythm

• Free-Running (nonentrained) type

• Shift Work Disorder

• Advanced Sleep Phase Disorder (ASP)

Increasing geriatric population coupled with rising prevalence of chronic disorders are some of the major factors driving the growth of CRSD market globally. The global population is aging, especially in developed countries that includes the U.S., Europe and Japan. It has been estimated that the global geriatric population would rise from 760 million (11%) in 2011 to 2 billion (2050). Thus, increasing geriatric population accentuates the growth of this market. However, lack of awareness among the patient population is one of the restraining factors for this market.

Geographically, North America and Europe accounted for the largest share of the global CRSD market owing to increasing geriatric population and rising prevalence of chronic diseases. According to Eurostat (European Commission) report in 2013, around 17.8% of the European population was above the age of 65 years. Thus, this increase in geriatric population propels the growth of CRSD in European region.

Vanda Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, VU University Medical Center, U.S. Centers of...